Inflammation and Coronary Artery Disease: Insights From Genetic Studies

Canadian Journal of Cardiology

Volumn 28, Issue 6, 2012, Pages 662-666

  McPherson, Ruth ^a   Davies, Robert W ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCL2; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHROMOSOME 6P; CHROMOSOME 9P; CORONARY ARTERY DISEASE; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; INFLAMMATION; REVIEW;

BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HLA-C ANTIGENS; HUMANS; INFLAMMATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84869085145     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.05.014     Document Type: Review

References (38)

1. McPherson R., Pertsemlidis A., Kavaslar N., et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007, 316:1488-1491.
2. Helgadottir A., Thorleifsson G., Manolescu A., et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007, 316:1491-1493.
3. Samani N.J., Erdmann J., Hall A.S., et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007, 357:443-453.
4. Schunkert H., Konig I.R., Kathiresan S., et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 2011, 43:333-338.
5. Dandona S., Stewart A.F., Chen L., et al. Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J Am Coll Cardiol 2010, 56:479-486.
6. Helgadottir A., Thorleifsson G., Magnusson K.P., et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet 2008, 40:217-224.
7. Shea J., Agarwala V., Philippakis A.A., et al. Comparing strategies to fine-map the association of common SNPs at chromosome 9p21 with type 2 diabetes and myocardial infarction. Nat Genet 2011, 43:801-805.
8. Pasmant E., Laurendeau I., Heron D., Vidaud M., Vidaud D., Bieche I. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 2007, 67:3963-3969.
9. Visel A., Zhu Y., May D., et al. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature 2010, 464:409-412.
10. Jarinova O., Stewart A.F., Roberts R., et al. Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol 2009, 29:1671-1677.
11. Holdt L.M., Teupser D. Recent studies of the human chromosome 9p21 locus, which is associated with atherosclerosis in human populations. Arterioscler Thromb Vasc Biol 2012, 32:196-206.
12. Kotake Y., Nakagawa T., Kitagawa K., et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene 2010, 30:1956-1962.
13. Yap K.L., Li S., Munoz-Cabello A.M., et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 2010, 38:662-674.
14. Harismendy O., Notani D., Song X., et al. 9p21 DNA variants associated with coronary artery disease impair interferon-gamma signalling response. Nature 2011, 470:264-268.
15. Kathiresan S., Voight B.F., Purcell S., et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009, 41:334-341.
16. Peden J.F., Hopewell J.C., Saleheen D., et al. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet 2011, 43:339-344.
17. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
18. Duewell P., Kono H., Rayner K.J., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
19. Tabas I., Williams K.J., Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007, 116:1832-1844.
20. Hansson G.K., Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011, 12:204-212.
21. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011, 17:1410-1422.
22. Zernecke A., Shagdarsuren E., Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 2008, 28:1897-1908.
23. Zernecke A., Bot I., Djalali-Talab Y., et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 2008, 102:209-217.
24. Zernecke A., Bidzhekov K., Noels H., et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009, 2:ra81.
25. Reilly M.P., Li M., He J., et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 2011, 377. 383-02.
26. Naitza S., Porcu E., Steri M., et al. A genome-wide association scan on the levels of markers of inflammation in Sardinians reveals associations that underpin its complex regulation. PLoS Genet 2012, 8:e1002480.
27. Davies R.W., Wells G.A., Stewart A.F., et al. A genome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complex. Circ Cardiovasc Genet 2012, 5:217-225.
28. Lahoute C., Herbin O., Mallat Z., Tedgui A. Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol 2011, 8:348-358.
29. Swanberg M., Lidman O., Padyukov L., et al. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 2005, 37:486-494.
30. Dwyer J.H., Allayee H., Dwyer K.M., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004, 350:29-37.
31. Ozaki K., Ohnishi Y., Iida A., et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002, 32:650-654.
32. Koch W., Hoppmann P., Michou E., et al. Association of variants in the BAT1-NFKBIL1-LTA genomic region with protection against myocardial infarction in Europeans. Hum Mol Genet 2007, 16:1821-1827.
33. Schuett H., Luchtefeld M., Grothusen C., Grote K., Schieffer B. How much is too much?. Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost 2009, 102:215-222.
34. Abeywardena M.Y., Leifert W.R., Warnes K.E., Varghese J.N., Head R.J. Cardiovascular biology of interleukin-6. Curr Pharm Des 2009, 15:1809-1821.
35. Sarwar N., Butterworth A.S., Freitag D.F., et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012, 379:1205-1213.
36. Hingorani A.D., Casas J.P. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet 2012, 379:1214-1224.
37. Boekholdt S.M., Stroes E.S. The interleukin-6 pathway and atherosclerosis. Lancet 2012, 379:1176-1178.
38. Schultz O., Oberhauser F., Saech J., et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS ONE 2010, 5:e14328.